

**VANCOUVER HOSPITAL & HEALTH SCIENCES CENTRE
PHARMACY SERVICES
DRUG DATA SHEET**

DRUG NAME

Azacitidine

ALTERNATE NAME

Mylosar, 5-Azacitidine, AZA-CR

MANUFACTURER

supplied by the National Cancer Institute

STRENGTH

100 mg

DOSAGE FORM

Vial

INDICATIONS

- Neoplastic agent used in acute myelogenous leukaemia, acute lymphocytic leukaemia and Myelodysplastic syndrome

DOSAGE AND ADMINISTRATION

- IV, SC: 1. 50-200 mg/m² /day for 5-10 days, repeated at 2-3 week intervals.
2. 75 mg/m²/day for 7 days; repeated q 4 weeks
 - SC: The volume may be too large to administer as a single injection. The doses may be split into multiple injections at different sites. Injection sites should be rotated on a daily basis. (Maximum volume per injection site= 2.5 ml. May need to make more than one syringe.)
 - Dosage for iv is a rough guide only. Information for IV dosing is very dated.
 - Drug preparation:
 1. SC: 100 mg vial + 4 ml SWFI or NS. The drug does not go into solution but a slurry is formed. DO NOT inject slurry IV. Reconstituted solution should be used within 30 minutes.
 2. IV: 100 mg vial + 19.9 ml SWFI to yield a 5 mg/ml solution.
- Stability at RT:
Lactate Ringers solution: 0.2 mg/ml ---1.9 h; 2 mg/ml ---- 2.9 h
Normal Saline: 0.2 mg/ml---1.9 h; 2 mg/ml---2.4 h

KNOWN SIDE EFFECTS*

- >10%: Coma (at doses 300-750 mg/m²), nausea, vomiting, diarrhea, mucositis, leukopenia, thrombocytopenia
- 1-10%: hypotension, coma, rash, hepatic abnormalities, renal toxicity (azotemia, hypophosphatemia, tubular acidosis)
- sc injection: moderate to severe burning pain; slightly raised violaceous tender skin lesion at the injection site. Onset

SPECIAL PRECAUTIONS

- make under biohazard hood
- slow administration of drug is recommended to prevent hypotension

*** REPORT ANY ADVERSE DRUG REACTIONS TO THE PHARMACY**

July 03, 02